0 244

Cited 14 times in

Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.

 Hye Jin Choi  ;  Byoung Chul Cho  ;  Sang Joon Shin  ;  Seong Ha Cheon  ;  Jong Yul Jung  ;  Joon Chang  ;  Se Kyu Kim  ;  Joo Hyuk Sohn  ;  Joo Hang Kim 
 Cancer Chemotherapy and Pharmacology, Vol.61(2) : 309-313, 2008 
Journal Title
 Cancer Chemotherapy and Pharmacology 
Issue Date
Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Carcinoma, Small Cell/drug therapy* ; Carcinoma, Small Cell/pathology ; Combined Modality Therapy ; Endpoint Determination ; Etoposide/administration & dosage ; Female ; Hematologic Diseases/chemically induced ; Humans ; Lung Neoplasms/drug therapy* ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Patient Compliance ; Salvage Therapy* ; Topotecan/administration & dosage
Etoposide ; Irinotecan ; Small Cell Lung Cancer ; Topotecan ; Eastern Cooperative Oncology Group Performance Status
PURPOSE: The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer. PATIENTS AND METHODS: From October 2003 to May 2005, 23 patients who have failed to the previous irinotecan and platinum chemotherapy received intravenous topotecan 1 mg/m2 (day 1-5) and etoposide 80 mg/m2 (day 1-3). Treatment was repeated every 21 days for a maximum of 6 cycles. RESULTS: Twelve patients were refractory to first-line chemotherapy. Seventeen patients (73.9%) were male and the median age was 63 years. ECOG performance status was 0-1 in 13 (56.5%) patients. The median cycles of chemotherapy was three. Twenty-one patients were assessable for response evaluation. The overall response rate was 17.4% (0 CR, 4 PR, 7 SD, 10 PD) under the intent-to-treat analysis. Two sensitive case patients and two refractory case patients achieved partial response. After a median follow-up of 20.8 months, median progression free survival was 4.7 months and median overall survival was 9.5 months. The estimated 1-year survival rate was 38.7%. All patients were assessable for toxicity and major toxicities were myelosuppression. Grade 3/4 neutropenia and thrombocytopenia occurred in 18 (78.3%) and 12 (52.2%) patients, respectively. Grade 3/4 febrile neutropenia occurred in two patients (8.7%) and infection in three patients (13.0%). There was one treatment-related death due to pneumonia. CONCLUSION: This salvage regimen showed modest efficacy and manageable toxicities. Further study will be required in recurrent SCLC patients pretreated irinotecan and platinum.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Se Kyu(김세규)
Kim, Joo Hang(김주항)
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Chang, Joon(장준) ORCID logo https://orcid.org/0000-0003-4542-6841
Cheon, Seong Ha(전성하)
Jung, Jong Yul(정종열)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
Choi, Hye Jin(최혜진) ORCID logo https://orcid.org/0000-0001-5917-1400
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.